JP2003514025A5 - - Google Patents

Download PDF

Info

Publication number
JP2003514025A5
JP2003514025A5 JP2001537965A JP2001537965A JP2003514025A5 JP 2003514025 A5 JP2003514025 A5 JP 2003514025A5 JP 2001537965 A JP2001537965 A JP 2001537965A JP 2001537965 A JP2001537965 A JP 2001537965A JP 2003514025 A5 JP2003514025 A5 JP 2003514025A5
Authority
JP
Japan
Prior art keywords
aplidine
use according
formulated
infusion
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001537965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003514025A (ja
Filing date
Publication date
Priority claimed from GBGB9927006.8A external-priority patent/GB9927006D0/en
Priority claimed from GB0005701A external-priority patent/GB0005701D0/en
Priority claimed from GB0007639A external-priority patent/GB0007639D0/en
Priority claimed from GB0015496A external-priority patent/GB0015496D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Application filed filed Critical
Priority claimed from PCT/GB2000/004349 external-priority patent/WO2001035974A2/en
Publication of JP2003514025A publication Critical patent/JP2003514025A/ja
Publication of JP2003514025A5 publication Critical patent/JP2003514025A5/ja
Pending legal-status Critical Current

Links

JP2001537965A 1999-11-15 2000-11-15 ガンのアプリジン治療 Pending JP2003514025A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB9927006.8 1999-11-15
GBGB9927006.8A GB9927006D0 (en) 1999-11-15 1999-11-15 Aplidine treatment of cancers
GB0005701.8 2000-03-09
GB0005701A GB0005701D0 (en) 2000-03-09 2000-03-09 Antitumor utility of aplidine
GB0007639.8 2000-03-29
GB0007639A GB0007639D0 (en) 2000-03-29 2000-03-29 Antitumour and anti-angiogenic compound
GB0015496.3 2000-06-23
GB0015496A GB0015496D0 (en) 2000-06-23 2000-06-23 Antitumour and anti-angiogenic compound
GB0025209.8 2000-10-13
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers

Publications (2)

Publication Number Publication Date
JP2003514025A JP2003514025A (ja) 2003-04-15
JP2003514025A5 true JP2003514025A5 (enExample) 2008-01-10

Family

ID=27515929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001537965A Pending JP2003514025A (ja) 1999-11-15 2000-11-15 ガンのアプリジン治療

Country Status (27)

Country Link
US (1) US20090298752A1 (enExample)
EP (1) EP1229922B1 (enExample)
JP (1) JP2003514025A (enExample)
KR (1) KR100518986B1 (enExample)
CN (1) CN1423564A (enExample)
AT (1) ATE363910T1 (enExample)
AU (1) AU780417B2 (enExample)
BG (1) BG65381B1 (enExample)
BR (1) BR0015811A (enExample)
CA (1) CA2391502A1 (enExample)
CY (1) CY1106825T1 (enExample)
CZ (1) CZ302498B6 (enExample)
DE (1) DE60035120T2 (enExample)
DK (1) DK1229922T3 (enExample)
ES (1) ES2288486T3 (enExample)
HK (1) HK1045648B (enExample)
HU (1) HUP0203906A2 (enExample)
IL (1) IL149488A0 (enExample)
MX (1) MXPA02004862A (enExample)
NO (1) NO330719B1 (enExample)
NZ (1) NZ518847A (enExample)
PL (1) PL200922B1 (enExample)
PT (1) PT1229922E (enExample)
RU (1) RU2261104C2 (enExample)
SI (1) SI1229922T1 (enExample)
SK (1) SK287762B6 (enExample)
WO (1) WO2001035974A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
BR0114604A (pt) 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
EP1435991B1 (en) * 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
KR20060002778A (ko) * 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
JP4584245B2 (ja) 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 多発性骨髄腫治療用のアプリジン
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
EP2117539B1 (en) * 2006-11-03 2010-09-01 Nerviano Medical Sciences S.r.l. A method of administering an antitumor compound
RU2360712C1 (ru) * 2007-10-02 2009-07-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения местно-распространенного неоперабельного рака прямой кишки
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
CN101965191A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
CN103463020B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗肾癌药物中的应用
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
ATE74761T1 (de) * 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
DE69431071T2 (de) * 1993-12-29 2003-03-20 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
EP0914116B1 (en) * 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
WO1998050048A1 (en) * 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
ES2272462T3 (es) * 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU1305302A (en) * 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
BR0114604A (pt) * 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US6610399B1 (en) * 2000-11-17 2003-08-26 Structural Technologies, Llc Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems
EP1435991B1 (en) * 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
KR20060002778A (ko) * 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
JP4584245B2 (ja) * 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 多発性骨髄腫治療用のアプリジン
AU2004224418A1 (en) * 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments

Similar Documents

Publication Publication Date Title
CA2401569A1 (en) Low dose entecavir formulation and use
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
HUP0100437A2 (hu) Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
JP2001515712A5 (enExample)
JP2002528502A5 (enExample)
CA2066403A1 (en) Transmucosal dosage form
CA2389235A1 (en) Controlled release hydrocodone formulations
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
JP2006514092A5 (enExample)
CA2503810A1 (en) Therapeutic agent for fibromyalgia
BG106171A (en) Compositions and uses of et743 for treating cancer
WO2000041504A3 (en) Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
JP2004537500A5 (enExample)
JP2002523437A5 (enExample)
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
JP2002522501A5 (enExample)
JP2002530353A5 (enExample)
MY124465A (en) Reduction of infarct volume using citicoline
JP2002540148A5 (enExample)
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
EP1561462A3 (en) Anti arrhytmic composition and methods of treatment
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
WO1990004977A3 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon